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Crafting the Perfect Cure? Embryonic CRISPr Editing and Equality of Access 
Introduction: 
“CRISPr” stands for clustered regularly interspaced palindromic repeats.1 CRISPr based 
technologies are transforming the state of life sciences around the world.2 Biotechnology has 
advanced through the advent of next generation sequencing technologies, allowing for 
researchers to identify individual genotypes quickly and thoroughly and thus identify the genetic 
locations of complex diseases.3 By locating the genetic loci of diseases, physicians can provide 
more adequate treatment to their patients and recommend lifestyle changes to mitigate disease.4 
Genome-editing tools advance biotechnology a step further by permanently mitigating or 
eliminating diseases through selective modification of the genome.5  
CRISPr has emerged as the premier gene editing tool over its predecessors, zinc-finger 
nucleases “ZFNs” and transcription activator-like effector nucleases “TALENs.”6 ZFN and 
TALEN are comparatively limited because of the need to engineer a new version of the editing 
protein for each genetic target.7 CRISPr only requires a slight alteration to target new sites.8 
CRISPr is currently used to generate and engineer changes in thousands of organisms.9 CRISPr 
can cure diseases, increase crop yields, and even increase disease resistance in plants and 
animals, but much of the spotlight on CRISPr involves controversy.10 The media presence of 
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CRISPr has been taken over by talks of the dystopian future of “designer babies,” children 
engineered to have augmented traits.11 This controversy was stirred when researcher He Jiankui 
announced he edited the germline genome of two twin girls to make them genetically resistant to 
HIV.12 Germline edits are controversial because they create heritable changes.13 The results of 
the experiment were met by widespread consternation by scientists, ethicists, and the public.14 
The experiment was not peer reviewed, went against globally shared research norms and ethics, 
failed to comply with government regulations, and overall was performed by staff that lacked 
qualifications, training, and experience.15 Suffice to say, He deviated from research norms.16  
The resulting public fallout has raised concerns that the future of the field may be in 
jeopardy.17 Fred Lanner, a stem-cell scientist at Karolinska University in Stockholm remarked, 
“the negative focus is, of course, not good,” others like Jonathan Kimmelman, a bioethicist 
specializing in human trials of gene therapies at McGill University in Montreal, Canada, argues 
swift action after scandal could drive global cooperation and regulation “that would stimulate, 
not hinder, meaningful advance in this area.”18 Due to the He scandal, there has been a conflation 
in public sentiment between blatant research infractions and the moral permissibility of heritable 
gene editing.19 Studies demonstrate there is no real consensus on the public opinion of the moral 
permissibility of heritable gene editing.20 Health care professionals must ensure that public 
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understanding of emerging gene editing techniques is driven by careful reflection, racially and 
ethnically informed problem solving, high ethical standards, and not scandal.21 Discussions about 
CRISPr germline editing should not strictly devolve into talks of ethics surrounding 
augmentation and engineering children to embody ideal traits.22  By only focusing on 
augmentation and scandal, public discussions on the ethics of the therapeutic applications of 
CRISPr will be overshadowed.23 A line should be drawn between CRISPr as a medical 
treatment, and as a means of human augmentation. In the near future CRISPr could become one 
of the staple therapies in the assisted reproductive technology “ART” framework.24 
The rise of IVF and PGT technology has allowed for the reduction of incidences of Tay-
Sachs disease in the Ashkenazi Jewish community, rescuing families from the debilitating 
childhood disease.25 Other communities that suffer from genetic diseases see reproductive gene 
editing as an additional tool for carrier screening and assisted  fertility to ensure the conception of 
healthy children.26 CRISPr germline editing provides a path to eliminate fatal and debilitating 
monogenetic diseases, and its introduction into the ART framework could compliment 
preimplantation genetic testing “PGT,” diagnoses.27 
This paper argues that CRISPr germline editing is a novel technology that may be utilized 
to cure heritable diseases, including diseases that are historically associated with ethnic and 
racial minority communities. However, out-of-pocket costs for CRISPr germline therapy will 
likely be prohibitively expensive due to the novel nature of the technology and the historic prices 
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of other gene therapies. Additionally, because CRISPr germline editing necessitates in vitro 
fertilization “IVF,” to cure and then implant embryos, the treatment will likely be classified as an 
infertility benefit for insurance purposes. Under the current state law regime there is likely to be 
insufficient coverage for CRISPr, thus enhancing inequality to ethnic and racial minorities that 
disproportionately suffer from genetic diseases. An expansion of state law mandates to require 
private insurance coverage for infertility benefits including IVF, PGT, and CRISPr germline 
editing will likely increase coverage for ethnic and racial minorities and thus prevent further 
exacerbation of historic inequities in access to treatment. 
In Part I this paper will address how CRISPr technology and gene editing operate 
generally, how the CRISPr technique works clinically, describe the specific applications of 
CRISPr with a focus on CRISPr germline therapies, and discuss the advantages and concerns of 
CRISPr germline therapies. In Part II this paper will provide the predicted monetary costs of 
CRISPr germline therapy considering both the historic costs of gene therapies and the costs 
associated with the ART framework. Part II will also discuss specific insurance provider 
coverage of existing infertility benefits. Part III analyzes state insurance laws regarding infertility 
coverage and ART therapy. In Part IV, this paper will address historic racial inequities in access 
to ART treatments and how an expansion of ART and CRISPr coverage will help address the 
prevalence of certain genetic diseases in ethnic and racial minorities. Part V concludes with a call 
for careful reflection and inclusive problem solving to ensure ethical standards in gene editing 




Part I: Gene Editing, CRISPr Technology, and Applications 
A. Gene Editing and CRISPr Generally 
“Gene editing” refers to the precise insertion, knockout, and alteration to the genome, 
genetic code, of an organism.28 Gene editing tools were once restricted to few select labs, but 
thanks to CRISPr gene therapy research has bloomed and now even a high school student can 
perform gene editing experiments.29 Older gene editing models produced a genetically altered 
mouse in a year or two, but now with CRISPr complex mouse models can be produced within a 
couple months.30 CRISPr is not the first site-specific gene therapy used for gene alteration, but 
where it revolutionized the field was in its comparative speed and simplicity.31 CRISPr 
technology can modify DNA in organisms and cultured cells quickly, precisely, efficiently, and 
for relatively cheap.32 CRISPr is thus prime for use in gene function studies, gene therapy 
studies, drug development, and the production of modified crops and livestock.33 CRISPr can 
facilitate the precise editing of genes in both mature and developing organisms.34 Genome 
editing with CRISPr seeks to edit genes through “knockout” by inhibiting genes with deleterious 
function and “knock-in” by restoring function to mutated genes.35 
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B. The CRISPr Technique 
CRISPr is naturally found in bacterial genomes and plays a role in bacterial anti-viral 
defense, this action is similar to the human immune response.36 CRISPr repairs the bacterium’s 
DNA after a viral attack.37 CRISPr is composed of a guide RNA strand “sgRNA”, which is used 
to detect the presence of viral DNA in the bacterium’s genetic code, and a specialized enzyme 
known as “Cas,” which carries the RNA around the cell.38 If the guide RNA detects viral DNA, 
the Cas enzyme will bind to the viral sequence and cut the DNA at that site.39 The bacterium’s 
genetic sequence will then be repaired, and the virus will not be able to reproduce.40 This process 
of destruction and subsequent repair of a bacterium’s genetic sequence proved critical to deriving 
the genetic tool CRISPr-Cas9.41 There are many variants of the Cas enzyme, but Cas9 is the 
variety of Cas enzyme with the most clinical understanding.42 The CRISPr-Cas9 complex is 
often referred to simply as CRISPr.43 
CRISPr-Cas9 is known for its versatility, Cas9 can precisely cut double stranded breaks 
in DNA that are user directed.44 To edit a cell of interest, Cas9 and sgRNA need to be 
introduced, this is normally done through direct injection or a vector.45 The versatility of CRISPr 
comes from the customizability of the sequence of the sgRNA strand, which allows researchers 
to program Cas9 to make double stranded breaks at specific sites.46 After CRISPr cleaves the 
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desired DNA, repair mechanisms are initiated.47 There are two mechanisms of repair, non-
homologous end-joining “NHEJ” and homology-directed repair “HDR.”48 NHEJ is error prone 
because reconstruction occurs without a template and is therefore inappropriate if the desired 
outcome is to make a dysfunctional gene functional, but is excellent if gene inactivation is 
desired.49 HDR rebuilds the DNA via a template strand and is therefore more accurate but is less 
efficient than NHEJ repair.50 Improving HDR’s efficiency is a goal of clinical studies to improve 
the overall accuracy of CRISPr..51 
A key distinction made in CRISPr human genome editing is between somatic cell 
therapies and germline cell therapies.52 In somatic editing, alterations to the cells are not passed 
on because changes are limited to body cells.53 In germline editing, alterations to the cells are 
heritable because changes are made to cells that pass on genetic information.54 Germline editing 
is controversial because of the inherent risks involved with introducing heritable alterations into 
the genome.55  
CRISPr germline genome editing “GGE,” is used to modify the cells of future organisms 
through genetic alterations of sperm, eggs, or fertilized zygotes.56 CRISPr GGE necessitates the 
use of IVF, all published studies utilizing human CRISPr GGE have utilized IVF zygotes.57 
PGT, previously known as preimplantation genetic diagnosis “PGD,” identifies genetically 
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healthy zygotes in an IVF cohort that will have the highest chances of implantation and can be 
used to screen for genetic disease.58 Patients with a familial history of heritable disease may 
apply for a PGT-M test to identify and discard embryos in the cohort that carry a disease-causing 
allele.59 Implementing CRISPr GGE first requires PGT to test embryos for the disease trait, then 
CRISPr would be applied to all embryos, and PGT would be applied again to ensure the genetic 
corrections occurred.60  
In somatic cell editing, CRISPr edits can occur ex vivo where cells are modified outside 
of the patient and reintroduced, or in vivo where CRISPr is directly delivered to the patient’s 
body to edit cells.61 There are advantages and challenges with both ex vivo and in vivo methods.62 
The advantage for ex vivo procedures are that the procedures are done externally, meaning the 
patient is not directly exposed to gene alterations and there is greater control of the process.63 
The challenges to ex vivo procedures are maintaining the survival and original function of the 
cells outside the patient long enough for gene alteration to occur, and culturing enough cells for 
successful reintroduction to the body.64 For in vivo treatments, CRISPr can be delivered 
intravenously or through local injection to specific tissues.65 The advantages of in vivo 
procedures are that because they are done intravenously or in site-specific areas, there is no need 
to create an external cell culture and regraft the cells into the body.66 However, the challenges of 
in vivo procedures are the degradation of the CRISPr components in the body, the potential for 
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uneven distribution of CRISPr components at the site of injection, and less control of the overall 
procedure.67  
C. Specific Applications of CRISPr 
CRISPr is a rapidly developing technology and has many potential clinical applications.68 
Cancer immunotherapy and the correction of monogenetic disorders seem to be at the forefront 
of clinical research.69 This analysis of the applications of CRISPr will focus on CRISPr GGE 
therapy with brief mention of the applications of somatic CRISPr therapies.  
a. CRISPr GGE Applications 
The scientific community considers CRISPr GGE clinical applications premature, but 
future implementation has not been precluded.70 According to professional recommendations 
from the medical community, clinical CRISPr GGE acceptance and implementation requires 
adequate safety measures, improved efficacy of methodology, additional societal consensus 
approving the technology, and appropriate governance standards to be in place.71 The most likely 
application of CRISPr GGE would be its use to prevent the transmission of heritable diseases.72 
In the clinic CRISPr GGE would be paired with IVF to produce a genetically related child that 
does not possess a genetic trait associated with a given disease.73 The approach would be 
available to couples who present a combination of genotypes that would result in some of their 
children being afflicted by a genetic disease, are aware they are potential carriers, and wish to 
avoid passing the disease to their children.74 The primary alternative option for the couple would 
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be to use IVF coupled with PGT to culture, select, and implant a genetically related and 
unaffected embryo.75 
Theoretically, there are scenarios where PGT would be pointless.76 If both parents are 
homozygous for a recessive gene disorder all embryos would be homozygous recessive as well.77 
Only CRISPr GGE would prevent the transmission of the disorder.78 Additionally, if one or both 
parents are homozygous for an autosomal dominant disorder every embryo will inherit at least 
one copy of the dominant disease-causing allele.79 However, both incidences are relatively rare.80 
Homozygosity for severe dominant disorders is often lethal at the embryonic level, meaning the 
number of sexually mature individuals with homozygous dominant alleles in the general 
population is relatively low.81 In the United States, the number of homozygous Huntington’s 
disease cases is in the dozens, meaning the probability of needing CRISPr GGE therapy for this 
application is minimal.82 For homozygous recessive diseases like sickle-cell disease “SCD” and 
Tay-Sachs, the incidence of individuals in the United States that are homozygous recessive are 1 
in 3,289 and 1 in 100,000 respectively for the general population.83 However, the incidence of 
SCD jumps to 1 in 500 for African Americans and the incidence of Tay-Sachs jumps to 1 in 
3600 for those of Ashkenazi Jewish descent because these diseases have a disproportionate 
impact on those communities.84 The estimated number of patients that benefit from CRISPr GGE 
may be considered relatively rare even in these communities when accounting for the incidence 
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of disease, reproductive age, and fertility rates.85 However, that does not justify diminishing the 
significance of the technology and how the option may benefit affected families.86 
Another potential application of CRISPr GGE would be to perform a procedure known as 
a “rescue embryo.”87 A rescue embryo describes a scenario where PGT testing could screen for 
embryos in the cohort with the disease trait, and those embryos would then be isolated and 
corrected using CRISPr GGE.88 This method would increase the overall number of viable 
embryos in the cohort.89 With current technology CRISPr GGE is most effectively used at the 
point of fertilization to avoid mosaicism in the embryonic cells as they divide.90 Mosaicism 
describes when not all cells in the embryo or organism have the same DNA.91 So CRISPr needs 
to be applied to all embryos in the cohort to achieve the desired changes.92 However, a method 
could potentially be developed to efficiently edits all cells in a multicellular embryo to reduce 
mosaicism.93 Prior genetic testing, isolation, and correction of embryos would then become a 
possibility.94 Additionally, CRISPr GGE may be the only strategy for an IVF patient with a 
genetic condition, that conceived only affected embryos and cannot complete additional cycles 
of IVF because of advancing age, disease, or prohibitive cost.95 Genetic enhancement for disease 
resistance may also be a possibility but is unlikely to have widespread adoption due to ethical 
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concerns. These ethical concerns are pervasive for the genetic enhancement of complex traits 
like intelligence.96  
In one experiment, CRISPr GGE was used to save human induced pluripotent stem cells 
and mice from the deleterious gene that causes spinal muscular atrophy “SMA.”97 The 
experiment was a proof of concept to determine if CRISPr could therapeutically intervene in 
SMA and other RNA-splicing diseases.98 SMA is a degenerative motor illness that in severe 
cases leads to muscle weakness, muscle degradation, and eventually death.99 SMA is the most 
common inherited cause of infant mortality in the world, and 98 percent of SMA patients are 
homozygous for the deletion of an SMN1 gene.100 Results showed CRISPr, “rescued the SMA 
phenotypes in human induced pluripotent stem cells and in germline-corrected SMA mice.”101 
The lifespan of the SMA mice improved from about 400 days to approximately 600 days.102 The 
mice saved by CRISPr GGE disruption demonstrated increased lifespans, increased body weight 
and motor function, and increased motor neurons.103 The results were inconclusive as to the 
feasibility of CRISPr having the same effect in humans, but still provide a proof-of-concept for 
CRISPr’s ability to rescue SMA mice from a debilitating disease.104   
Various animal models have utilized CRISPr GGE including primates.105 Studies have 
also utilized GGE to correct mutations with heart disease and beta-thalassemia.106 However, 
 
96 Niemiec & Howard, supra note 32 at 888.  
97 Jin-Jing Li et al., Disruption of splicing-regulatory elements using CRISPR/Cas9 rescues spinal muscular atrophy 




101 Id. at 93. 
102 Id. 
103 Id. at 97. 
104 Id. at 99. 
105 Robert Ranisch, Germline genome editing versus preimplantation genetic diagnosis: Is there a case in favour of 
germline interventions?, 34 Bioethics 2020 60 (2019). 
106 Id. at 60-1. 
13 
 
additional testing needs to be performed before CRISPr GGE gene editing can become part of 
everyday patient care.107  Somatic therapies are not always the optimal choice.108 For example, in 
cases where early-onset or congenital diseases occur, the symptoms of the disease would already 
affect the child before somatic therapy could ameliorate the condition.109 In lysosomal storage 
disorders the disease manifests virtually no symptoms in infants but within the first days of life 
the disease proves fatal.110 Additionally, in the case of Duchenne muscular dystrophy “DMD” 
symptoms manifest within the first five years of life, but after the symptoms have appeared the 
condition is virtually irreversible.111 Huntington’s disease also presents an issue for somatic 
therapy in that the targeted tissue designated for therapy is hard to access in a fully formed 
child.112 CRISPr GGE comparatively can easily target a gene within a gamete or zygote in vitro 
when a parent is a known carrier of the genetic disorder.113 There is no need to worry about 
targeting multiple widespread and different types of tissue to accomplish therapy.114  
Potential targets of CRISPr GGE in cardiovascular medicine include hypertrophic 
cardiomyopathy “HCM,” DMD, and other heritable arrhythmic disorders; all three diseases are 
heritable and lack effective therapy making them prime for CRISPr GGE therapy.115  HCM is a 
cardiac disease that leads to degenerative heart failure.116 DMD is a disease that leads to 
progressive muscular weakness and ultimately heart failure.117 Heritable arrhythmic disorders 
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cause sudden cardiac death in young children.118 All these disorders are caused by a single gene 
mutation.119 In one United States study, viable human embryos were modified to correct for the 
genetic traits that cause HCM.120 HCM is responsible for the most cardiac deaths under the age 
of thirty.121 The study proved promising, but additional studies are needed to improve the 
efficiency of the CRISPr complex before clinical applications may be considered.122 
b. CRISPr Somatic Therapy Applications 
While this paper does not focus on the applications of somatic gene therapies it is 
noteworthy that these therapies have seen success in clinical cancer immunotherapy and gene 
disruption therapy.123 In 2018, the FDA approved a CRISPr clinical trial for cancer 
immunotherapy, the goal of the clinic was to modify T-cells to target several forms of cancer 
with relapsed tumors.124 Another successful clinical trial using CRISPr treatment aimed to 
provide therapeutic benefits to patients with SCD and later beta-thalassemia by utilizing gene 
disruption to increase fetal hemoglobin levels.125 The previous trials both used ex vivo 
modification of cells, which is the most common form of somatic CRISPr therapy.126 
Approaches using in vivo techniques have been limited in their clinical applicability because of 
inadequate access to target tissues. However, some organs, like the eye, are accessible.127 In one 
promising treatment, CRISPr components can be delivered directly into the retina to treat 
patients with Leber congenital amaurosis “LCA,” a monogenetic disease that causes childhood 
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blindness.128 Somatic CRISPr therapies are better suited to treat complex disorders like artery 
disease and atherosclerosis because of the complicated interplay between genetics and 
environmental factors that cause these diseases.129 
D. Limitations and Advantages of CRISPr GGE 
a. CRISPr GGE Limitations 
CRISPr GGE experiments create hefty public discourse surrounding issues of safety and 
ethical supervision.130 Safety issues involve a contradiction between promising technological 
outcomes and faults caused by the technology’s immaturity.131  Safety concerns of CRISPr GGE 
include off-target effects, chimeric embryos, and the bad-gene good-gene contradiction.132 Off-
target effects occur when the CRISPr complex mismatches with a non-target DNA sequence and 
an unintended mutation is introduced.133 This posits the problem that the unintended mutation is 
now heritable and passed on to the next generation despite its effects being unknown.134. 
Research is underway to improve the specificity of CRISPr and the method of detection for off-
target effects to increase the feasibility of CRISPr GGE therapies.135 Another concern are 
chimeric embryos, otherwise known as mosaicism.136 Mosaicism in GGE is caused by the Cas9 
protein not fully degrading before the zygote replicates, which results in a mosaic of cells that 
have different DNA.137 The hazard of mosaicism depends on degree of change and the 
chromosome where the alteration occurred.138 Using an enzyme that is more precise and 
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controlled in its timing of enzymatic activity may limit the effects of mosaicism.139 The bad gene 
good gene contradiction is best described as researchers not fully comprehending all the positive 
and negative effects of genes, which necessitates a humility when modifying genes to delete a 
perceived bad gene.140 For example, the mutation of hemoglobin that causes SCD also prevents a 
patient from catching malaria.141 Human CRISPr GGE cannot be approached from the 
perspective of simply deleting bad traits, rather additional research needs to be done on the 
cause-and-effect relationships between genes before permanent genomic changes occur.142  
b. CRISPr GGE Advantages 
The clinical value of CRISPr GGE has many applications, CRISPr GGE aims to increase 
the knowledge and understanding of human development as well as gene functionality, 
ameliorate genetic defects during development, and treat diseases.143 CRISPr GGE could 
potentially cure the 6000 known human genetic diseases that afflict twelve percent of the world’s 
population.144 CRISPr GGE has an advantage over somatic therapies for treating monogenetic 
diseases with a wide range of heritability like muscular dystrophy, and genetic diseases that are 
difficult to treat in fully grown individuals like Huntington’s disease.145 Population control of 
disease is a broader justification for CRISPr GGE, such that through its use the prevalence of 
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benefits to society, like the economic gains of diminished costs to the healthcare system, against 
the potential harm to individuals through the introduction of unknown heritable mutations.147 
Part II: Monetary Costs of IVF, PGT, and CRISPr GGE 
According to Stanford bioethicist Mildred Cho, PhD, “Gene therapy is not the same as 
taking a pill from the pharmacy, it’s more like getting an organ transplant…Cancer 
immunotherapy already costs in the hundreds of thousands of dollars per year. There’s no way 
that gene-edited treatments are going to be any less expensive.”148 New biotechnologies used to 
treat diseases often present a high price tag because gene therapies are difficult to research, are 
inordinately costly to push through clinical trials, are uncertain in success rate, serve a limited 
population, and are by their nature permanent.149 Gene therapies are not like insulin, the aim of 
gene therapy is to pay for the treatment once and be cured.150 For example, the Novartis drug 
Zolgensa is an FDA approved one-time gene therapy treatment of SMA.151 The drug is priced at 
$2.125 million and insurers may pay this amount in yearly installments of $425,000 per year.152 
The price of Zolgensa was calculated by Novartis as half the approximate $4 million cost of 
managing the disease over the course of a decade.153 Another expensive gene therapy is the 
Sarepta Therapeutics drug Eteplirsen.154 Eteplirsen is a novel drug aimed to treat DMD, however 
the drug was largely denied coverage by insurance companies due to the drug’s poor efficacy in 
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clinical trials and its $750,000 annual price tag.155 There is hope for CRISPr GGE coverage, 
insurance providers rarely refuse to cover novel therapies and work through prescription benefit 
managers to reduce pharmaceutical drug prices if the therapy is proven effective.156  
An important consideration for CRISPr price is patent protection.157 As CRISPr has 
progressed toward clinical testing, the dispute over patent ownership has expedited, primarily 
because the market valuation of the CRISPR technology is in the billions.158 The dispute for 
CRISPr ownership is between the University of California, along with the University of Vienna 
and Umea University, collectively “UC”, and the Broad Institute who is partnered with MIT and 
Harvard, collectively “Broad Institute.”159 Both UC and the Broad Institute have filed for patent 
ownership to ascertain a monopoly over the CRISPr market in the United States and in 
Europe.160 The costs of this heated litigation are likely to be passed on to consumers when the 
litigation resolves and CRISPr enters clinical trials.161 
If CRISPr GGE therapy were to underperform in clinical trials and was exorbitantly 
priced due to patent pressures, it is likely insurance companies would deny coverage.  
To approximate the cost of CRISPr GGE therapy it is important to draw comparisons to 
IVF and PGT because CRISPr GGE treatment requires use of both technologies.162 ART 
therapies are most pervasive in affluent countries.163 IVF and PGT present the necessary 
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framework for couples affected by genetic disorders to conceive a healthy child.164 The 
demographic most likely to utilize ART therapies are wealthier patients, which is defined by a 
household income of greater than $100,000 per year.165 Under the current insurance regime, 
patients often must pay first and seek reimbursement later.166 Insurers frequently do not agree to 
coverage in advance of treatment and instead make a coverage decision on a case-by-case 
basis.167 Given the unpredictability of length and cost of ART treatment, stress and uncertainty 
are necessarily increased in patients facing the hurdle of relying on coverage for treatment.168 
This stress is exacerbated by couples having to budget both ART treatment and adding a new 
child to their household.169 Cost raises the ethical concern of how much couples will value 
having a child; couples are faced with an ethical dilemma of choosing between solvency and 
procreation.170 On average, an IVF cycle can cost from $9,226 to $12,513 per cycle, with PGT 
adding an additional $2,500 to $6000 per cycle.171 According to the CDC, successful pregnancy 
and live birth often requires more than one cycle of ART.172 Factors that increase the required 
number of cycles include age, weight, height, previous IVF usage, and prior pregnancies.173  
Cost remains the most salient factor and barrier to couples deciding to undergo ART 
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IVF if their insurance provider does not provide coverage.175 Affordable reproductive 
technologies allow more couples the ability to avoid genetically prone diseases and ensure a 
higher quality of life for their children.176 Most U.S. insurers including United Healthcare, Aetna, 
Cigna, and Anthem cover genetic testing.177 To qualify, individuals usually need to attend 
genetic counseling or present a genetic risk based on family history.178 United Healthcare 
explicitly carves out screening options for Ashkenazi Jewish carrier screening, whereas other 
insurers typically enumerate genetic diseases without mention of ethnicity or race.179 Genetic 
testing is also available to consumers for a few hundred dollars; this option may be helpful for 
individuals who lack insurance or want definitive privacy in their genetic results from their 
insurer.180Additionally, some health insurance companies provide coverage for IVF and PGT 
independent of state mandates.181 Aetna provides coverage for IVF when the policyholder has 
ART benefits and the procedure is medically necessary.182 For Aetna, medically necessary is 
defined as medical diagnosis of infertility, which in turn means less invasive fertility methods 
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detectable single gene mutations.184 Cigna also offers coverage for the combination of IVF and 
PGT if there is a medical diagnosis of infertility, of which the definition is similar to Aetna.185 
United Healthcare includes coverage of IVF for reasons of infertility, but causes outside of 
infertility must be reviewed in accordance with the benefit plan.186 PGT is offered by United 
Healthcare for the diagnosis of known genetic disorders, unless there are specific exclusions in a 
particular plan.187 It is important to recognize that the costs of CRISPr GGE and IVF are 
significantly less than the lifelong medical costs accrued because of the genetic disorder.188 For 
this reason, insurance providers may be incentivized to cover treatments like CRISPr that reduce 
healthcare costs over the life of the individual.189 
Currently, two options exist for prospective parents with a known genetic risk to ensure 
their biological children do not inherit the genetic condition.190 These options are prenatal 
diagnosis “PND,” and PGT.191 PND involves natural conception and a subsequent test for 
genetic abnormalities.192 If the condition is found, the pregnancy may be terminated.193 PGT 
screens for embryos free of the genetic disease.194 PND is covered by almost every public and 
private insurer in the United States.195 PGT functions in the same diagnostic capacity as PND, 
just in earlier stages of pregnancy.196 Therefore, cost is likely the primary reason insurers deny 
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PGT coverage since PND is a cheaper alternative.197 The United States Centers for Medicare & 
Medicaid Services “CMS” present guidelines for what qualifies as medically necessary care.198 
Medically necessary care consists of “health care services or supplies needed to diagnose or treat 
an illness, injury, condition, disease or its symptoms and that meet accepted standards of 
medicine.”199 PGT certainly qualifies as a diagnostic procedure, but it may be overshadowed in 
the insurance framework by the cheaper diagnostic procedure PND.200 The argument for PGT as 
a treatment procedure seems attenuated.201 However, if CRISPr GGE were to meet the accepted 
standards of medicine threshold through clinical research, it could fulfill the treatment 
component of the medically necessary definition for ART therapy since CRISPr GGE directly 
alters the genome to treat disease.202 Perhaps if the ART framework met both definitions of 
medically necessary, insurers would be more prone to extend coverage.203  
Part III: State Law ART Regulations  
 A comparative analysis of state private insurance coverage laws regulating infertility 
treatments demonstrates a great disparity between even the states that mandate some form of 
infertility coverage.204 Some states may cover fertility testing alone, whereas others cover 
multiple cycles of IVF.205 The federal government does not mandate infertility coverage as an 
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mandate insurance companies to provide coverage.206 Currently, nineteen states mandate some 
form of coverage for infertility treatment, whereas thirty-one states and DC have remained silent 
on the issue.207 There does seem to be a trend towards mandating coverage; since 2018, 
Colorado, Delaware, New Hampshire, and Utah have all passed legislation addressing infertility 
coverage.208 Colorado’s mandate will take effect in January of 2022, New Hampshire’s mandate 
took effect in January of 2020, and Maryland will expand its coverage as of 2021.209 Fifteen 
states have laws requiring health plans to cover at least some infertility treatments.210 Colorado 
will join these states in 2022.211 Two states, Texas and California, require group health plans to 
offer at least one policy with infertility coverage, but employers can opt for a different plan.212 
One state, Louisiana, prohibits coverage from being excluded based on the diagnosis of a 
correctable medical condition that results in infertility.213 This law does not mandate IVF or 
other fertility drug treatments.214 Nine states that lack a mandate to cover, as well as DC, have a 
benchmark plan to provide most individual and small group plans sold in the state with 
diagnostic and possibly treatment services.215 Thirteen states have laws that mandate IVF 
coverage including, Arkansas, Colorado in 2022, Connecticut, Delaware, Hawaii, Illinois, 
Maryland, Massachusetts, New Hampshire, New Jersey, New York, and Rhode Island.216 
Including Colorado, sixteen states have laws mandating at least genetic testing or other 
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diagnostic tests.217 The CDC has deemed Illinois, Massachusetts, New Jersey, and Rhode Island 
comprehensive coverage states.218 A comprehensive coverage state is defined as offering at least 
four egg retrievals within the state mandate.219 No state mandates PGT.220 Many mandate to 
cover states have exemptions for small employers that employ less than fifty people as well as 
religious exemptions.221 State laws also do not apply to self-insured plans.222 A self-insured plan 
describes when an employer pays for the health services of its workers rather than by purchasing 
health insurance.223 
In California, group insurers must offer coverage for infertility treatments and diagnosis, 
but they are not required to provide the coverage, nor do employers need to include it in their 
insurance plans.224 The state mandate notably excepts IVF from coverage.225 Infertility is defined 
by the law as a demonstrated condition, recognized by a licensed physician and surgeon as a 
cause of infertility; or the inability to conceive pregnancy or fully carry a live birth to term after a 
year or more of sexual relations absent contraception.226 The law further carves out an exception 
for religious employers stating they do not offer coverage that is inconsistent with the 
organization’s religious or ethical principles.227 There was a notable amendment that specified 
treatment, “shall be offered and, if purchased, provided without discrimination on the basis of 
age, ancestry, color, disability, domestic partner status, gender, gender expression, gender 
identity, genetic information, marital status, national origin, race, religion, sex, or sexual 
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orientation.”228 As evidenced by the law, California’s state mandate of infertility coverage is 
extremely conservative in its application. 
New Jersey law requires health insurers with 50 or more employees that provide 
pregnancy related coverage of medically necessary expenses incurred in diagnosis and treatment 
of infertility, including IVF, artificial insemination, diagnosis and testing, embryo transfer, 
surgery, medications, gamete intrafallopian transfer, zygote intrafallopian transfer, 
intracytoplasmic sperm injection, and four completed egg retrievals per lifetime of the covered 
person.229 IVF is further expanded, coverage includes both using donor eggs and when an 
embryo is transferred to a surrogate.230 Notably infertility treatments that are experimental or 
investigational are not covered as well as cryopreservation of gametes.231 Coverage of IVF, 
zygote intrafallopian transfer, and gamete intrafallopian transfer are only required if the patient 
has used all reasonable less expensive options covered by insurance and still has not become 
pregnant, the maximum number of egg retrievals has not been used, the person is under 46 years 
old, and the procedures are performed at facilities conforming to the American Society for 
Reproductive Medicine “ASRM” or the American College of Obstetricians and Gynecologists 
“ACOG.”232 New Jersey defines infertility broadly in accordance with the ASRM and ACOG to 
include a disease or condition that results in abnormal function of the reproductive system 
including where a couple cannot get pregnant after two years of unprotected sex, where the 
female partner is under the age of 35; or one year of unprotected sex where the female partner is 
over the age of 35; or when a couple is unable to carry a pregnancy to term.233 New Jersey also 
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has a similar religious organization exemption to California where coverage can be excluded if it 
is contrary to a religious employer’s bona fide religious tenets.234 New Jersey’s laws are 
comprehensive in their mandate to cover, especially when compared to California. 
Illinois law also requires insurers to provide coverage for infertility treatment, but is even 
more liberal in that employers with fewer than 25 employees do not need to provide coverage.235 
Infertility is defined in Illinois as the inability to conceive after one year of unprotected sexual 
intercourse or the inability to sustain a pregnancy.236 Otherwise, Illinois coverage provides for 
the diagnosis and treatment of infertility, IVF, uterine embryo lavage, embryo transfer, artificial 
insemination, gamete intrafallopian transfer, zygote intrafallopian transfer and low tubal ovum 
transfer.237 To utilize IVF, zygote intrafallopian transfer, and gamete intrafallopian transfer the 
patient must not have been able to sustain a successful pregnancy through less costly infertility 
treatment covered by insurance.238 A religious exemption is also carved out.239 Additionally, the 
patient is covered by four egg retrievals unless a live birth occurs, then only two more retrievals 
are covered.240 Compared to New Jersey and California, Illinois law places the least amount of 
restrictions on ART treatment. Although both New Jersey and Illinois are comprehensive in their 
mandates, fundamental differences can still be observed in how that coverage is attained, most 
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Part IV: CRISPr GGE and Benefits to Ethnic and Racial Minorities 
A. Inequity of Access to ART therapy 
Under the current insurance regime there is concern that if CRISPr GGE were clinically 
available it would be prohibitively expensive, not covered by private insurance, and thus limited 
to socio-economic classes that can afford out-of-pocket treatment. Lack of access to treatment 
would exacerbate already existing health inequities in ethnic and racial minorities. An expansion 
of state law mandates to require private insurance coverage for infertility benefits including IVF, 
PGT, and CRISPr GGE will likely increase coverage for ethnic and racial minorities and thus 
address disparate ethnic and racial outcomes in health.  
In the United States race and ethnicity are often linked to a disproportionate access to 
healthcare affecting primarily Hispanic and Black patients.241 In states that mandate insurance 
coverage of IVF, the utilization of ART therapy by Hispanic and Black Non-Hispanic women, 
aged fifteen to forty-four, nearly doubled when compared to states without an insurance mandate 
for IVF treatment.242 The main factor contributing to ART use is affordability, when ART 
therapy is not covered by insurance it can impose great financial hardship on couples.243 Socio-
economic factors can indicate ART use; women with higher income and higher levels of 
educational attainment are more likely to utilize ART.244 Residential segregation of certain 
minority groups into areas with lesser economic opportunities can present an economic barrier to 
access fertility options.245 Even when coverage is mandated, rates of ART use among Hispanic 
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and Black women are still less than White and Asian/Pacific Islander women.246 However, this 
disparity is thought to be caused by out-of-pocket expenses like deductibles and copays, as well 
as non-economic factors such as the negative communal stigma on infertility.247 To reduce this 
disparity, health care providers could provide incentives for infertility clinics to operate in lower 
income areas.248 Increasing awareness, affordability, and expanding access to low-income areas 
may be enough to defeat communal stigmas and increase equitable access to ART therapy.249 
Minority communities are aware of disparities in the distribution of cutting-edge medical 
technology, and that potential genetic enhancements from CRISPr may exacerbate health 
disparities in these communities.250 American socioeconomic status has a strong association with 
race and ethnicity, which raises concerns that if CRISPr treatments were limited to out-of-pocket 
payments, racial and ethnic minorities would not equally share in the fruits of gene therapy.251 
Gene therapy may pose a risk of widening health disparities, but if scientists, physicians, and 
healthcare policymakers pledge to ensure justice in gene therapy, the technology may be used as 
a tool to eventually reduce health inequities.252 
B. Prevalence of Certain Genetic Conditions 
Fairness and equitable access must be at the forefront in developing GGE CRISPr policy. 
Underserved patients must share in equal access to ground-breaking biotechnologies through a 
collaborative dialogue and policy decisions informed by the needs of underserved populations. 
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for the governance of human genome editing: the science should promote wellbeing, increase 
transparency to the community, take due care in research studies, follow the standards of 
responsible science, respect persons right to autonomy and integrity, be fair in the distribution of 
risks and burdens, and support transnational cooperation and collaboration.253  
Clinical applications of CRISPr GGE for ethnic and racial minorities will be to correct 
mutations in zygotes that cause fatal or debilitating monogenetic diseases.254 Certain 
monogenetic diseases have a higher incidence rate in ethnic and racial minority communities.255 
Such diseases include SCD, Ty-Sachs, and beta-thalassemia.256 The corrected gene would then 
be heritable and passed on to the next generation.257 The prevalence of genetic diseases in these 
communities would thus be reduced.258 Reducing incidence of disease would diminish economic 
strains and increase the number of healthy children born.259 Economic strains include the cost of 
lifetime management of disease for the individual and their family.260 Economic strains on the 
healthcare system would also be reduced.261 
The most common monogenetic disorder caused by a single point mutation is SCD, 
making the disease a prime target for CRISPr GGE therapy.262 SCD also has a disproportionate 
impact on those of African descent.263 Currently, more than 100,000 people in United States live 
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with SCD, the incidence of which is disproportionately Black.264 SCD occurs in one in every 365 
Black births, with sickle cell trait “SCT” occurring one in every thirteen Black births.265 Sickle 
cell trait describes a condition where the child has one abnormal allele but does not show the 
severity of SCD symptoms.266 The first signs of SCD appear during the first year of life, usually 
around five months.267 The symptoms can range from mild to severe, and the disease worsens 
over time.268 The characteristic symptoms include acute pain crises, swelling in the hands and 
feet known as hand-foot syndrome, acute chest pain similar in feeling to pneumonia, as well as 
anemia and the associated symptoms of dizziness, tiredness, irritability, and difficulty 
breathing.269 SCD requires a lifetime of management of lifestyle and potentially necessitates a 
lifetime of medications.270 The SCD community has been historically disenfranchised and there 
has been little advancement on the ease of access of SCD treatments.271  
Tay-Sachs disease is a fatal genetic disorder that causes the progressive degeneration of 
the central nervous system.272 Children born with Tay-Sachs appear unaffected at birth and 
symptoms do not appear until about four or six months of age.273 The child will begin to lose 
motor skills and gradually lose the ability to see, hear, and swallow.274 By two years old, most 
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impaired, paralyzed, and unable to respond.276 Death usually occurs by age four.277 Tay-Sachs 
disease has no cure.278 The incidence of Tay-Sachs is much higher in individuals of Ashkenazi 
Jewish descent, with an estimated one in twenty-five individuals being a carrier for the 
disease.279 Since Tay-Sachs does not have an effective cure, possesses no genetic benefits to the 
individual, and has a disparate impact on an ethnic minority, CRISPr GGE therapy will be an 
optimal treatment to reduce the incidence of Tay-Sachs in the Ashkenazi Jewish community.280  
Beta-thalassemia is a blood condition that impacts the production of hemoglobin.281 The 
disease has two forms, thalassemia intermedia and thalassemia major.282 Thalassemia intermedia 
appears in early childhood and is characterized by symptoms of weakness and anemia.283 
Thalassemia major can become life-threatening, children with major develop progressively 
worse anemia and have reduced immunity.284 Thalassemia major may require regular blood 
transfusions.285 Beta-thalassemia has a high incidence amongst the Hispanic community, with 
between one in thirty and one in fifty individuals being a carrier for the disease.286  
Part V: Conclusion 
All people should share in the breakthroughs of scientific discovery, classes of people 
should not be denied access to technology that can ensure a healthier life for their progeny based 















can afford out-of-pocket costs, future generations of already marginalized communities will be 
further disenfranchised through the denial of access to therapy that seeks to diminish genetically 
prone diseases. In equity and in fairness, state infertility mandates should be expanded to afford 
ethnic and racial minorities a greater opportunity to share in the fruits of emerging 
biotechnologies. Minimum standards that need to be established before CRISPr GGE can be 
adopted include, the development of acceptable methodologies for measuring off-target effects, 
establishing an acceptable threshold of allowable off-target mutations, and setting precedent for 
when CRISPr GGE may be utilized.287 Ethical considerations must be undertaken in human GGE 
research to set a boundary between therapeutic treatment and genetic enhancement of 
individuals. Human GGE research must ensure the principles of beneficence and justice are 
respected through research and innovation. Healthcare professionals can ensure justice and 
ethical regulation by defining the relevant stakeholders of GGE research, establishing ethics 
committees to review and supervise research, and by maintaining public contact to stay informed 
on the needs of society.  
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